ATE239491T1 - Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen - Google Patents
Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinenInfo
- Publication number
- ATE239491T1 ATE239491T1 AT96917968T AT96917968T ATE239491T1 AT E239491 T1 ATE239491 T1 AT E239491T1 AT 96917968 T AT96917968 T AT 96917968T AT 96917968 T AT96917968 T AT 96917968T AT E239491 T1 ATE239491 T1 AT E239491T1
- Authority
- AT
- Austria
- Prior art keywords
- neurotoxins
- methods
- admixtures
- neurotoxin
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Peptides Or Proteins (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46576795A | 1995-06-06 | 1995-06-06 | |
PCT/US1996/008534 WO1996039167A1 (en) | 1995-06-06 | 1996-06-04 | Improved compositions and methods for chemodenervation using neurotoxins |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE239491T1 true ATE239491T1 (de) | 2003-05-15 |
Family
ID=23849078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT96917968T ATE239491T1 (de) | 1995-06-06 | 1996-06-04 | Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen |
Country Status (8)
Country | Link |
---|---|
US (1) | US6087327A (de) |
EP (1) | EP0773788B1 (de) |
AT (1) | ATE239491T1 (de) |
AU (1) | AU6034396A (de) |
DE (1) | DE69627963T2 (de) |
DK (1) | DK0773788T3 (de) |
ES (1) | ES2198484T3 (de) |
WO (1) | WO1996039167A1 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW574036B (en) | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
US6545126B1 (en) * | 1999-03-18 | 2003-04-08 | Wisconsin Alumni Research Foundation | Chimeric toxins |
DE19925739A1 (de) * | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
US6143306A (en) * | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
US6337075B1 (en) | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
US6261572B1 (en) | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
US20060269575A1 (en) * | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
US20030138460A1 (en) * | 2000-02-08 | 2003-07-24 | Allergan, Inc | Methods of treating animals with botulinum toxin pharmaceutical compositions |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US8632785B2 (en) * | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
CN1258379C (zh) * | 2000-02-08 | 2006-06-07 | 阿勒根公司 | 肉毒杆菌毒素药物组合物 |
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
IL153734A0 (en) * | 2000-06-28 | 2003-07-06 | Ira Sanders | Methods for using tetanus toxin for beneficial purposes in animals (mammals) |
US7273722B2 (en) * | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
US7115399B2 (en) * | 2001-07-31 | 2006-10-03 | Allergan, Inc. | Pinna reflex assay |
US20030113349A1 (en) * | 2001-12-18 | 2003-06-19 | Coleman William P. | Topically applied clostridium botulinum toxin compositions and treatment methods |
US7022329B2 (en) * | 2002-02-25 | 2006-04-04 | Allergan, Inc. | Method for treating neurogenic inflammation pain with botulinum toxin and substance P components |
US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
NZ540425A (en) * | 2002-12-20 | 2009-03-31 | Botulinum Toxin Res Ass Inc | Pharmaceutical botulinum toxin compositions |
US7276244B2 (en) * | 2004-02-12 | 2007-10-02 | Philip Radovic | Methods of treating abnormalities of the first metatarsophalangeal joint of the foot |
US20050220821A1 (en) * | 2004-03-31 | 2005-10-06 | Allergan, Inc. | Pressure sore treatment |
US8323666B2 (en) | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
US20070128226A1 (en) * | 2005-12-01 | 2007-06-07 | Philip Radovic | Methods of treating pain associated with abnormalities of the first metatarsophalangeal joint of the foot |
US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
WO2009139739A1 (en) * | 2006-02-14 | 2009-11-19 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion |
EP2015773A4 (de) * | 2006-04-27 | 2010-05-05 | Anterios Inc | Prüfung der effekte topischer verabreichung chemisch denervierender pharmazeutika |
US20080113051A1 (en) * | 2006-11-13 | 2008-05-15 | Allergan, Inc. | Methods for alleviating tattoo pain |
CA2671447A1 (en) | 2006-12-01 | 2008-06-12 | Anterios, Inc. | Amphiphilic entity nanoparticles |
US9107815B2 (en) * | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
ES2761664T3 (es) * | 2008-06-26 | 2020-05-20 | Anterios Inc | Entrega dérmica |
US9066851B2 (en) | 2008-12-04 | 2015-06-30 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
KR20190014125A (ko) * | 2011-01-24 | 2019-02-11 | 안테리오스, 인코퍼레이티드 | 나노입자 조성물, 이의 제형, 및 그의 용도 |
US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
WO2014066916A2 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
PT3436054T (pt) | 2016-09-13 | 2019-11-19 | Allergan Inc | Composições de toxina clostridial não proteicas estabilizadas |
CN117731591A (zh) | 2016-11-21 | 2024-03-22 | 艾里奥治疗公司 | 大试剂的透皮递送 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5183462A (en) * | 1990-08-21 | 1993-02-02 | Associated Synapse Biologics | Controlled administration of chemodenervating pharmaceuticals |
US5401243A (en) * | 1990-08-21 | 1995-03-28 | Associated Synapse Biologics | Controlled administration of chemodenervating pharmaceuticals |
WO1994000481A1 (en) * | 1992-06-23 | 1994-01-06 | Associated Synapse Biologics | Pharmaceutical composition containing botulinum b complex |
US5562907A (en) * | 1993-05-14 | 1996-10-08 | Arnon; Stephen S. | Method to prevent side-effects and insensitivity to the therapeutic uses of toxins |
EP1099445A3 (de) * | 1993-06-10 | 2001-09-05 | Allergan, Inc. | Behandlung neuromuskulärer Erkrankungen und Zuständen mit unterschiedlichen Botulinum Serotypen |
JP4249802B2 (ja) * | 1993-06-10 | 2009-04-08 | アラーガン、インコーポレイテッド | 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
-
1996
- 1996-06-04 DE DE69627963T patent/DE69627963T2/de not_active Expired - Lifetime
- 1996-06-04 AU AU60343/96A patent/AU6034396A/en not_active Abandoned
- 1996-06-04 DK DK96917968T patent/DK0773788T3/da active
- 1996-06-04 EP EP96917968A patent/EP0773788B1/de not_active Expired - Lifetime
- 1996-06-04 AT AT96917968T patent/ATE239491T1/de not_active IP Right Cessation
- 1996-06-04 ES ES96917968T patent/ES2198484T3/es not_active Expired - Lifetime
- 1996-06-04 WO PCT/US1996/008534 patent/WO1996039167A1/en active IP Right Grant
-
1998
- 1998-01-30 US US09/016,123 patent/US6087327A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1996039167A1 (en) | 1996-12-12 |
US6087327A (en) | 2000-07-11 |
DK0773788T3 (da) | 2003-09-01 |
ES2198484T3 (es) | 2004-02-01 |
EP0773788A1 (de) | 1997-05-21 |
DE69627963D1 (de) | 2003-06-12 |
EP0773788B1 (de) | 2003-05-07 |
DE69627963T2 (de) | 2004-03-04 |
AU6034396A (en) | 1996-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE239491T1 (de) | Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen | |
DE69940439D1 (de) | Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe | |
ATE553118T1 (de) | Modifiziertes clostridiumtoxin mit geänderter biologischer persistenz | |
DE69101557D1 (de) | Enzymatische waschmittelzusammensetzung und verfahren zum stabilisieren der enzyme. | |
BG103977A (en) | Low molecular rotamase enzymic activity inhibitors | |
BR9917152A (pt) | Composição para tratamento terapêutico ou profilático de infecção estreptocócica e método e uso respectivos | |
BR9909129A (pt) | Conjugados de proteases | |
CA2296720A1 (en) | Use of botulinum toxin in the preparation of a pharmaceutical composition for treating a prostate disorder in a mammal | |
CA2424242A1 (en) | Methods for treating muscle injuries | |
CA2406367A1 (en) | Method for treating pain by peripheral administration of a neurotoxin | |
ATE255418T1 (de) | Neurotoxine zur behandlung von pankreatischen krankheiten | |
KR970064594A (ko) | 노화방지용 화장품 조성물 | |
ATE355076T1 (de) | Zusammensetzungen und methoden zur systemischen verabreichung von oralen impfstoffen und therapeutischen wirkstoffen | |
FI925787A0 (fi) | Proteolytiska enzymers sackarinderivatinhibitorer | |
WO2001082961A3 (en) | Methods for treating bone tumors | |
DK0418945T3 (da) | Forgreningsenzym og dets anvendelse | |
DE69813200D1 (de) | Verbesserung der wundheilung mit cm101/gbs-toxin | |
Martinez et al. | Isolation of a hemorrhagic toxin from Mojave rattlesnake (Crotalus scutulatus scutulatus) venom | |
AU2888702A (en) | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy | |
Smyth et al. | The potent mitogen Pasteurella multocida toxin is highly resistant to proteolysis but becomes susceptible at lysosomal pH | |
NO951277L (no) | Desulfatohirudin med höy molekylvekt | |
ATE210460T1 (de) | Zusammensetzungen, welche adp-ribosyltransferase- aktivität aufweisen und methoden für ihre herstellung und die verwendung derselben | |
PE46999A1 (es) | Inhibidores de cicloalquilo de la enzima farnesiltransferasa de las proteinas | |
ATE313628T1 (de) | Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen | |
Hambleton | Botulinum toxin: structure and pharmacology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |